Background
==========

Hormonal stimulation of ovarian epithelial cells has been proposed as a mechanism for carcinogenesis of the ovaries \[[@B1]\]. The evidence for sex steroid hormones playing a role in ovarian cancer is primarily indirect, based on animal and *in vitro*studies, as well epidemiological observations \[[@B1]\], while the relationship between circulating levels of sex steroids and ovarian cancer risk has not been clearly demonstrated \[[@B2],[@B3]\].

The sex steroid hormone-binding globulin (*SHBG*) gene regulates the action of sex steroid hormones by modulating their bioavailability to target tissues such as the ovaries \[[@B4]\]. The *SHBG*gene is located on the short arm of chromosome 17. A non-synonymous SNP in exon 8 results in an amino acid substitution of asparagine for aspartic acid (D356N, rs6259) in the SHBG protein, and the asparagine (N) allele of *SHBG*has been associated with elevated circulating levels of SHBG in post-menopausal women \[[@B5]-[@B7]\]. An additional SNP in the 5\' untranslated region (UTR) of *SHBG*has also been associated with elevated *SHBG*levels \[[@B6]\]. These data suggest that common variation in *SHBG*has functional relevance and thus, could affect the risk of hormonally-related cancers.

We performed a detailed assessment of common genetic variation in *SHBG*and evaluated the possibility of an association with ovarian cancer risk in the Polish Ovarian Cancer Study. We included SNPs in the *SHBG*3\' flanking gene ATPase, Na+/K+ transporting beta 2 polypeptide (*ATP1B2*) because of the observation of linkage disequilibrium (LD) that extends across *SHBG*and *ATP1B2*based on a re-sequencing study \[[@B8]\]. The enzyme encoded by *ATP1B2*is involved in establishing and maintaining the electrochemical gradients of Na and K ions across the plasma membrane. Inclusion of neighboring genes in studies of relationships between disease and common genetic variation is of interest because they could affect the regulation of the protein of interest.

Methods
=======

Study population
----------------

The Polish Ovarian Cancer Study is a population-based case-control study of ovarian cancer conducted among female residents of Warsaw and Lodz (Poland), 20--74 years of age. Eligible cases consisted of all women newly diagnosed with histologically confirmed ovarian carcinoma or a borderline tumor identified during the study period (June 2001 -- December 2003). We identified a total of 437 eligible cases. Most (76%) cases were idenditfied through a rapid ascertainment system in participating hospitals, and the remaining cases (24%) missed by this system were identified through cancer registries. Control women were randomly selected within matching strata from complete population lists (PESEL database) of Warsaw and Lodz residents from 2001 to 2004, and were frequency matched to cases on age (5-year groups) and study site (Warsaw and Lodz). Women who reported a previous diagnosis of ovarian cancer or bilateral oopherectomy were excluded as controls. Of the eligible cases and controls, 78% and 69%, respectively, agreed to participate in the study. The main reasons for non-participation among eligible subjects included: refusal to participate (11% cases and 24% controls); unable to locate (3% cases and 7% controls), and deceased (7% cases and \<0.1% controls). This resulted in 341 cases and 1994 controls participating in the main study.

All participants underwent a personal interview regarding known or suspected ovarian cancer risk factors. The median time from diagnosis to interview was 2.4 months, ranging from 5 days to one year. Of the interviewed women, 315 (92%) cases and 1911 (96%) controls provided a blood or buccal cell sample for DNA extraction; however, eight of these cases were excluded because of limited amounts of DNA or quality control problems. This report is limited to carcinomas; therefore 22 cases with borderline tumors and 21 cases with non-epithelial tumors were further excluded from the analyses, leaving 264 cases (241 with blood and 23 with buccal cell DNA). For costs-efficiency, we randomly selected a sample of 625 controls with blood DNA to approximate a 1:2 case:control ratio. Thus, final analyses included a total of 264 cases and 625 controls. All study participants were of Polish Caucasian origin. The study protocol was reviewed and approved by local and NCI Institutional Review Boards (IRBs). All participants provided written informed consent.

Genotyping
----------

Single nucleotide polymorphism (SNP) selection was based on a re-sequence analysis of *TP53*and its neighboring genes, which include *SHBG*and *ATP1B2*, performed in 94 healthy Norwegian women and 102 individuals in the SNP500 Cancer panel \[[@B8]\]. SNPs in *SHBG*and *ATP1B2*with a minor allele frequency \>0.05 were identified during a re-sequence analysis of all exons, evolutionarily conserved regions and promoter regions and were genotyped in the Polish Ovarian Cancer Study. Genotype analyses were performed at the Core Genotyping Facility (CGF) of the Division of Cancer Epidemiology and Genetics, NCI for 5 SNPs in *SHBG*(rs1799941, -67G\>A 5\'UTR; rs6257, IVS1-17T\>C; rs6259, Ex8+6G\>A (D356N); rs727428, 1121 bp 3\' of STP T\>C; and rs1641544 31959 bp 3\' of STP T\>C); and 5 SNPs in *ATP1B2*(rs1641536, -*8852T\>C*; rs1641535 -*8703T\>C*; rs1624085 x2G\>C; rs1641512, *Ex7+414G\>A*).

Description and methods for each genotype assay can be found at \[[@B9],[@B10]\]. Duplicated DNA pairs from 70 subjects in the study showed 100% concordance for all assays. Completion was ≥ 98% for all assays. We observed no significant departures from Hardy-Weinberg equilibrium in the control population.

Statistical Analyses
--------------------

As an estimate of relative risk, odds ratios (OR) and their 95% confidence intervals (CI) were derived from unconditional logistic regression models that included dummy variables for the matching factors, i.e. age in 5 year categories and study site (Lodz or Warsaw). The association between genotypes and ovarian cancer risk was tested using a trend test, except for rare alleles in which heterozygous and homozygous variants were combined. We evaluated heterogeneity in the ORs observed for the genotype analysis on the basis of age, number of lifetime ovulatory cycles and family history of ovarian and/or breast cancer in first degree relatives, by introducing interaction terms in logistic regression models. Number of lifetime ovulatory cycles was used as a measure of a women\'s potential ovulatory life, and was calculated as previously described \[[@B11]\].

Pairwise linkage disequilibrium (LD) was estimated between SNPs based on D\'and r^2^values using Haploview \[[@B12]\]. Block structure was determined using genotype data from the control population, and the solid spline of LD option (D\' threshold \> 0.80). Haplotype frequencies within each block, ORs and their 95%CIs were estimated using HaploStats (version 1.2.1) \[[@B13],[@B14]\]. A global score statistic, adjusted for the matching factors age (in 5 year categories) and study site (Lodz or Warsaw), was used to evaluate the overall difference in haplotype frequencies between cases and controls.

Results
=======

The cases included in this analysis were diagnosed at a mean (SD) age of 56.2 (11.0) years. Tumor characteristics include: 45% had serous carcinomas, 62% had distal metastases, and 52% had tumors with poor grade of differentiation (Table [1](#T1){ref-type="table"}). As expected, serous, mixed and unclassified tumors were frequently poorly differentiated (69%, 75% and 90%, respectively), with a lower percentage of poorly differentiated tumors among endometriod (36%) and mucinous (19%) carcinomas. Compared to control women, cases were more frequently nulliparous or had fewer full-term births, had a larger number of lifetime ovulatory cycles, and more frequently reported a first degree family history of a first-degree relative with ovarian or breast cancer (Table [1](#T1){ref-type="table"}). Cases were also less likely to have used oral contraceptives. These differences were consistent with known or suspected risk factors for ovarian cancer \[[@B15]\].

A map of LD in the control population across the 10 SNPs evaluated is shown in Additional file [1](#S1){ref-type="supplementary-material"}. Three of the evaluated polymorphisms (rs1641537, rs1641536 and rs1641535 in *ATP1B1*) showed strong correlations (pairwise r^2^\> 0.98) and, to avoid redundancy, only data for one of the correlated SNPs are shown in Table [2](#T2){ref-type="table"}. Genotypes with the variant alleles for the putative functional SNPs in *SHBG*, D356N (rs6259) and -67G\>A 5\'UTR (rs1799941), were less common among cases than controls; however, differences were not statistically significant (Table [2](#T2){ref-type="table"}). These two SNPs showed low correlation (r^2^= 0.03). Evaluation of joint effects suggested that subjects with genotypes carrying variant alleles for both SNPs could be at particularly low risk (OR (95%CI) for subjects with the rs6259 AG/GG and rs1799941 AG/GG genotypes (9 cases and 36 controls) was 0.47 (0.22--1.02), p = 0.06, compared to common homozygous for both SNPs (122 cases and 237 controls). However, the interaction between these two SNPs was not statistically significant (p = 0.15). None of the other SNPs evaluated were significantly associated with ovarian cancer risk. Associations with the SNPs evaluated in this report were not significantly modified by age, menopausal status, first degree family history of breast or ovarian cancer, or number of lifetime ovulatory cycles (data not shown). Associations were also not significantly modified by histological type or stage at diagnosis (data not shown).

Haplotype analyses including all non-redundant SNPs (i.e excluding rs1641536 and rs1641535 in *ATP1B1*) showed nine haplotypes with frequencies \>0.01, with no significant overall association with ovarian cancer risk (global p = 0.42; Table [3](#T3){ref-type="table"}). Only one haplotype, present in 5% of cases and controls, carried the D356N (rs6259) SNP and showed no significant association with risk compared to the haplotype carrying the common alleles for each of the SNPs evaluated (ATACCCCG). Although none of the individual haplotypes were significantly associated with risk, there was a borderline significant association for the most common haplotype (frequent in 35% of controls) which carried a variant for a SNP in the 5\'UTR of *SHBG*(rs1799941). Data were consistent with an inverse association for women carrying this haplotype (GTACCCCG) compared to the ATACCCCG haplotype (OR 95%CI = 0.77 (0.58--1.01); Table [3](#T3){ref-type="table"}).

Discussion
==========

This detailed evaluation of common genetic variation in *SHBG*including its neighboring gene *ATP1B2*, does not support a substantial association between common variants and ovarian cancer risk. However, the possibility of weak to modest associations could not be excluded.

The asparagine (N) allele of *SHBG*D356N and the variant allele of the -67G\>A 5\'UTR SNP in *SHBG*have been associated with elevated SHBG circulating levels \[[@B5]-[@B7]\]. Therefore, these SNP could result in a reduced bioavailability of estrogen or other sex-steroids, and a reduction in risk of hormonally-related cancers. Although the frequency of the genotypes with the variant alleles for these two SNPs was lower for cases than controls, differences were not statistically significant. A pentanucleotide (TAAAA)~n~repeat polymorphism, not measured in our study, has been found to be linked to the D356N SNP in Caucasian populations, as well as associated with elevated levels of SHBG \[[@B7]\]. Therefore, it is possible that functional changes not directly measured in our study might be related to risk. Given the lack of data from previous studies of ovarian cancer on the common variation in *SHBG*, further studies are needed to clarify potential relationships.

The main limitation of this study was limited power to detect weak to modest associations. Specifically, the study size provided 80% power to detect ORs of 1.5 or 0.7 for MAFs ranging from 0.10 to 0.50, assuming an additive mode of inheritance; and MAFs ranging from 0.20 to 0.35, assuming a dominant inheritance. However, the power to detect associations for MAF outside these ranges, recessive associations, or gene-gene/gene-environment interactions was low. Therefore, such associations could have missed in our study.

This population-based study has among the highest participation rate attained in population-based studies with collection of biological specimens. However, collection of DNA samples inevitably reduces overall participation rates and could introduce selection bias. This bias is unlikely to be of relevance in this report because the evaluated SNPs are unlikely to be related to potential selection factors. Further, the observed allele frequency for the *SHBG*D356N was similar to previously published studies among Caucasians \[[@B6]\], and the distribution of ovarian cancer risk factors in cases and controls was consistent with known or suspected risk factors for ovarian cancer \[[@B15]\].

Conclusion
==========

This report of a detailed assessment of genetic variation in *SHBG*including its neighboring gene *ATP1B2*, does not support a substantial association between common variation in this region and ovarian cancer risk. However, weak or modest associations could not be excluded, particularly a reduced risk of ovarian cancer hypothesized for the functional SNPs D356N and -67G\>A 5\'UTR. Therefore, further evaluation in larger study populations is warranted.
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Figures and Tables
==================

###### 

Personal and tumor characteristics of 264 ovarian cancer cases and 625 controls in the Polish Ovarian Cancer Study.

                                                                              Cases\* N = 264          Controls\* N = 625          P\*\*
  --------------------------------------------------------------------------- ----------------- ------ -------------------- ------ ----------
  Study site, N %                                                                                                                  
   Warsaw                                                                     177               67%    423                  68%    0.85
   Lodz                                                                       87                33%    202                  32%    
  Age, mean SD in years                                                       56.3              10.8   56.1                 10.8   0.83
                                                                                                                                   
  No. of full-term births, N %                                                                                                     
   Nulliparous                                                                50                19%    79                   13%    \<0.0001
   1                                                                          101               38%    176                  28%    
   2                                                                          94                36%    273                  44%    
   ≥ 3                                                                        19                7%     97                   16%    
  Number of ovulatory cycles, mean SD                                         410.9             71.1   398.1                81.3   0.03
                                                                                                                                   
  Use of oral contraceptive, N %                                                                                                   
   Never                                                                      245               94%    556                  90%    0.08
   Ever                                                                       16                6%     60                   10%    
                                                                                                                                   
  Currently having menstrual periods, N %                                                                                          
   No                                                                         182               71%    401                  66%    0.40
   Yes                                                                        75                29%    203                  34%    
   Unclear                                                                    7                 3%     20                   3%     
                                                                                                                                   
  Use of oral hormone replacement therapy among post-menopausal women                                                              
   Never                                                                      146               81%    325                  82%    
   Ever                                                                       35                19%    70                   18%    0.15
                                                                                                                                   
  Family history of breast or ovarian cancer in first-degree relatives, N %                                                        
   No                                                                         210               80%    553                  88%    0.001
   Breast cancer only                                                         26                10%    24                   4%     
   Ovarian cancer only                                                        26                10%    40                   6%     
   Both                                                                       2                 1%     8                    1%     
                                                                                                                                   
  **Tumor Characteristics**                                                                                                        
  Histology, N (%)                                                                                                                 
   Serous                                                                     118               45%                                
   Mucinous                                                                   26                10%                                
   Endometrioid                                                               58                22%                                
   Clear cell                                                                 14                5%                                 
   Mixed                                                                      18                7%                                 
   Others or unclassified                                                     30                11%                                
                                                                                                                                   
  Stage, N % distant                                                          110               62%                                
   Not staged or missing                                                      86                                                   
                                                                                                                                   
  Grade of differentiation, N %                                                                                                    
   Well                                                                       21                13%                                
   Moderate                                                                   59                35%                                
   Poor                                                                       88                52%                                
   Missing                                                                    96                                                   

\* Differences between the total number of cases and controls and frequencies shown in the table are due to missing data.

\*\* P values for categorical variables are based on chi squared tests, and on t-tests for continuous variables.

###### 

Risk of epithelial ovarian cancer and polymorphisms in *SHBG*and its 3\' neighbor *ATP1B2*, among 264 ovarian cancer cases and 625 controls in the Polish Ovarian Cancer Study\*

  Gene SNP                        Cases   Controls   OR\*\*   95% CI         P-trend
  -------------------------- ---- ------- ---------- -------- -------------- ---------
  ***SHBG***                                                                 
                                                                             
  rs1799941                  AA   144     278        1.00                    
  -67G\>A                    AG   118     287        0.79     0.59 -- 1.07   
  5\'UTR                     GG   23      57         0.79     0.46 -- 1.33   0.14
                                                                             
  rs6257                     TT   242     520        1.00                    
  IVS1-17T\>C                TC   41      91         0.97     0.65 -- 1.44   
                             CC   2       2          2.13     0.29 -- 15.3   0.75
                                                                             
  rs6259                     AA   254     547        1.00                    
  Ex8+6G\>A                  AG   30      72         0.89     0.57 -- 1.40   
  D356N                      GG   1       4          0.51     0.06 -- 4.65   0.72
                                                                             
  rs727428                   CC   119     264        1.00                    
  1121 bp 3\' of STP T\>C    CT   121     278        0.96     0.71 -- 1.30   
                             TT   45      81         1.25     0.81 -- 1.91   0.48
                                                                             
  rs1641544                  CC   261     580        1.00                    
  31959 bp 3\' of STP T\>C   CT   22      38         1.34     0.77 -- 2.33   0.30
                             TT   1       0                                  
                                                                             
  ***ATP1B2***                                                               
                                                                             
  rs1641537 \*\*\*           CC   215     486        1.00                    
  -9115T\>C                  CT   66      125        1.21     0.86 -- 1.71   
                             TT   3       8          0.90     0.23 -- 3.46   0.36
                                                                             
  rs1624085                  CC   116     246        1.00                    
  Ex2G\>C                    CG   120     292        0.86     0.64 -- 1.18   
                             GG   49      84         1.25     0.82 -- 1.90   0.60
                                                                             
  rs1641512                  GG   193     401        1.00                    
  Ex7+414G\>A                GA   80      195        0.86     0.63 -- 1.17   
                             AA   12      27         0.94     0.46 -- 1.90   0.42

\* Differences between the total number of cases and controls and frequencies shown in the table are due to missing genotype data.

\*\* Adjusted for age and city.

\*\*\* Highly correlated with *ATP1B1*rs1641536 (18852T\>C) and rs1641535 (-8703T\>c), r^2^\> 0.98, not shown in table to avoid redundancy.

###### 

Risk of epithelial ovarian cancer and *SHBG-ATP1B2*extended haploptypes, among 264 ovarian cancer cases and 625 controls in the Polish Ovarian Cancer Study

                                                Haplotype frequency   OR     95%CI   P                 
  ----------------- --- --- --- --- --- --- --- --------------------- ------ ------- ----------------- ------
  A                 T   A   C   C   C   C   G   0.26                  0.20   1.00    (reference\*\*)   
  G                 .   .   .   .   .   .   .   0.32                  0.35   0.77    0.58 -- 1.01      0.06
  .                 .   .   .   .   .   G   A   0.01                  0.02   0.43    0.14 -- 1.33      0.14
  .                 .   .   T   .   .   G   .   0.12                  0.11   0.89    0.60 -- 1.33      0.58
  .                 .   .   T   .   T   G   A   0.09                  0.09   0.83    0.56 -- 1.23      0.36
  .                 .   .   T   T   T   G   A   0.04                  0.03   1.22    0.70 -- 2.12      0.49
  .                 .   G   T   .   .   G   A   0.05                  0.05   0.81    0.50 -- 1.30      0.38
  .                 C   .   T   .   .   G   .   0.07                  0.07   0.81    0.53 -- 1.25      0.34
  G                 .   .   .   .   .   G   .   0.01                  0.02   0.51    0.17 -- 1.58      0.24
                                                                                                       
  Global p = 0.42                                                                                      

\* Polymorphic bases in 5\' to 3\' order: *SHBG*(rs1799941, rs6257, rs6259, rs727428, rs1641544); *ATP1B2*(rs16441537, rs1624085, rs1641512). Two *ATP1B2*SNPs (rs1641536 and rs1641535) highly correlated (r^2^\> 0.98) with rs1641537 are not included in the analyses.

\*\* The reference
